Skip to main content
The Good Peptides

Immune stimulation, considered alongside restraint

Reading list

Studies on the table

The cell experiments explain my interest in restraint. The human trials make the judgment harder. Both are here.

Cells and tissue effects

Start with the viral and bacterial stimulus comparison. Beside it sit the regulatory B-cell experiment, the bone-marrow-derived cell study of IDO, and the mouse study of intestinal toxicity during CTLA-4 blockade.

Cancer trials and synthesis

The randomised metastatic melanoma study supplies the tumour-response and numerical survival findings. The Cochrane review examines the wider trial record; the lung-cancer phase 2 study follows radiation pneumonitis using historical controls.

Hepatitis comparisons

The selection includes the entecavir combination meta-analysis in HBV-related cirrhosis, the peginterferon comparison in hepatitis B, and the hepatitis C trial with different overall and completer results. For the molecule itself, the precursor-cleavage study describes generating mature thymosin alpha-1 from prothymosin alpha.

  1. Dual effect of Thymosin α 1 on human monocyte-derived dendritic cell in vitro stimulated with viral and bacterial toll-like receptor agonists ↗
  2. Thymosin-α1 expands deficient IL-10-producing regulatory B cell subsets in relapsing-remitting multiple sclerosis patients ↗
  3. [An experimental study on the regulation of bone marrow-derived mesenchymal stem cells through indoleamine 2,3-dioxygenase signaling pathway by thymosin α1 for improving the immunosuppression mediated by T cell] ↗
  4. Thymosin α1 protects from CTLA-4 intestinal immunopathology ↗
  5. Large randomized study of thymosin alpha 1, interferon alfa, or both in combination with dacarbazine in patients with metastatic melanoma ↗
  6. Thymic peptides for treatment of cancer patients ↗
  7. The clinical efficacy and adverse effects of Entecavir plus Thymosin alpha-1 combination therapy versus Entecavir Monotherapy in HBV-related cirrhosis: a systematic review and meta-analysis ↗
  8. Efficacy of thymosin α-1 plus peginterferon α-2a combination therapy compared with peginterferon α-2a monotherapy in HBeAg-positive chronic hepatitis B: a prospective, multicenter, randomized, open-label study ↗
  9. Thymosin alpha-1 with peginterferon alfa-2a/ribavirin for chronic hepatitis C not responsive to IFN/ribavirin: an adjuvant role? ↗
  10. Generation of mature Nα-terminal acetylated thymosin α 1 by cleavage of recombinant prothymosin α ↗
  11. Efficacy of Thymosin α1 in Management of Radiation Pneumonitis in Patients With Locally Advanced Non-Small Cell Lung Cancer Treated With Concurrent Chemoradiotherapy: A Phase 2 Clinical Trial (GASTO-1043) ↗